Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The hospital has recently launched Radionuclide therapy
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The company will manufacture a cancer immunotherapy product from 2022
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
Subscribe To Our Newsletter & Stay Updated
